-
Mashup Score: 2Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC - 9 hour(s) ago
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC - 3 day(s) ago
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC #esocsm #hncsm #oncology https://t.co/Sel4VLSzXo
-
-
Mashup Score: 2Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC - 7 day(s) ago
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC #esocsm #hncsm #oncology https://t.co/Sel4VLSzXo
-
Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC #esocsm #hncsm #oncology https://t.co/Sel4VLSzXo